3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Transitional Cell
2
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Interventions
Carboplatin
6
Pemetrexed
4
pembrolizumab
3
Cisplatin
3
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
zipalertinib
1
zimberelimab
1
sacituzumab govitecan
1
pralsetinib
1
patritumab
1
camrelizumab
1
alectinib
1
Vinorelbine
1
Thrombin
1
Talc
1
TachoSil
1
TNFSF10 protein, human
1
Surveys and Questionnaires
1
Nivolumab
1
Injections
1
Fibrinogen
1
Erlotinib Hydrochloride
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Diseases
×
sacituzumab govitecan
×
Clear all
NCT06431633
2026-05-18
ARIAN
Fundación GECP
Phase 3
Recruiting
129 enrolled